The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

INTRODUCTION: The aim was to determine the effect of the Bruton tyrosine kinase (Btk)-selective inhibitor PCI-32765, currently in Phase I/II studies in lymphoma trials, in arthritis and immune-complex (IC) based animal models and describe the underlying cellular mechanisms. METHODS: PCI-32765 was ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Betty Y, Huang, Min Mei, Francesco, Michelle, Chen, Jun, Sokolove, Jeremy, Magadala, Padmaja, Robinson, William H, Buggy, Joseph J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239353/
https://www.ncbi.nlm.nih.gov/pubmed/21752263
http://dx.doi.org/10.1186/ar3400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239353/
https://www.ncbi.nlm.nih.gov/pubmed/21752263
http://dx.doi.org/10.1186/ar3400

Ejemplares similares